不可切除或转移性胃肠道间质瘤患者甲磺酸伊马替尼治疗前后血清成纤维细胞生长因子2的变化

Changes of serum fibroblast growth factor 2 levels before and after treatment with imatinib mesylate in patients with unresectable or metastatic gastrointestinal stromal tumor

目的探讨不可切除或转移性胃肠道间质瘤患者甲磺酸伊马替尼治疗前后血清成纤维细胞生长因子2（FGF2）水平变化。方法应用酶联免疫吸附法（ELISA）检测27例不可切除或转移性胃肠道间质瘤患者甲磺酸伊马替尼治疗前后血清FGF2，并进行比较。结果治疗前血清FGF2阳性率为63．0％（17／27），经甲磺酸伊马替尼治疗3个月后降为33．3％（9／27），二者间差异有统计学意义（χ2=4．08，P=0．039）。伊马替尼治疗3个月后复查CT，无完全缓解，部分缓解率51．9％（14／27），稳定率48．1％（13／27），无进展病例。结论不可切除或转移性胃肠道间质瘤患者血清FGF2阳性率升高，甲磺酸伊马替尼治疗可以降低不可切除或转移性胃肠道间质瘤患者血清FGF2水平。

Objective To explore changes of serum fibroblast growth factor 2 （FGF2） levels after treatment with imatinib mesylate in patients with unresectable or metastatic gastrointestinal sromal tumor. Methods Serum FGF2 levels （with ELISA） were determined in 27 patients with unresectable or metastatic gastrointestinal stromal tumor both before and after treatment with imatinib mesylate. Results Before treatment with imatinib mesylate, of 27 cases of unresectable or metastatic gastrointestinal stromal tumor, 17 cases （63.0 %） were found positive for serum FGF2, after treatment with imatinib mesylate, 9 cases （33.3 %） were found positive for serum FGF2 （P 〈 0.05）. Using imatinib mesylate for 3 months,complete remission rate was 0, partial remission rate was 51.9 % （14/27）, stable disease rate was 48.1% （13/27） and progressive rate was 0. Conclusion Patients with unresectable or metastatic gastrointestinal stromal tumor have elevated serum FGF2 levels. Imatinib mesylate treatment can reduce serum FGF2 levels in patients with unresectable or metastatic gastrointestinal stromat tumor.